EU/3/12/975

About

On 21 March 2012, orphan designation (EU/3/12/975) was granted by the European Commission to Ferring Pharmaceuticals A/S, Denmark, for carbetocin for the treatment of Prader-Willi syndrome.

The sponsorship was transferred to Voisin Consulting S.A.R.L., France, in March 2018.

Key facts

Active substance
Carbetocin
Disease / condition
Treatment of Prader-Willi syndrome
Date of decision
21/03/2012
Outcome
Positive
Orphan decision number
EU/3/12/975

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Voisin Consulting S.A.R.L.
64, Avenue Pierre Grenier
92100 Boulogne Billancourt
France
Tel. +33 1 41 31 83 00
E-mail: orphan@voisinconsulting.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating